$79.00
Manufacturer: Poland
Epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization; generalized tonic-clonic seizures; mixed forms of seizures. Finlepsin can be used as a monotherapy or as part of a combination therapy. Acute manic States; supportive therapy for bipolar affective disorders in order to prevent exacerbations or reduce the clinical manifestations of exacerbation. Alcohol withdrawal syndrome. Idiopathic trigeminal neuralgia and trigeminal neuralgia in multiple sclerosis (typical and atypical). Idiopathic neuralgia of the pharyngeal nerve.
Description
Finlepsin retard Storage
active substance: carbamazepine;
1 tablet contains carbamazepine 200 mg;
Excipients: ammonium methacrylate copolymer (type B) dispersion, triacetin, talc, methacrylate copolymer dispersion, crospovidone, colloidal anhydrous silica, magnesium stearate, microcrystalline cellulose.
Finlepsin retard Dosage form
Prolonged-release tablets.
Main physical and chemical properties: white or yellowish round flat clover-shaped tablets, with beveled edges, with a cross-shaped break line on both sides and 4 notches on the sides, with a smooth surface and solid edges and the same appearance.
Finlepsin retard Pharmacotherapeutic group
Antiepileptic drugs. ATX code N03A F01.
Pharmacological properties
Pharmacodynamics.
Anticonvulsant, a derivative of tricyclic iminostilbene. Shows antiepileptic, neurotropic and psychotropic activity. The exact mechanism of action of carbamazepine is unknown. The therapeutic effect is primarily due to the inhibition of synaptic transmission of excitation and thus – reducing the spread of seizures. At higher concentrations, carbamazepine causes a decrease in the conductivity of convulsive discharges. Reduces pain in trigeminal neuralgia. This effect is due to inhibition of synaptic transmission of stimuli in the spinal nucleus of the trigeminal nerve.
Pharmacokinetics.
After oral administration, carbamazepine is absorbed slowly and almost completely. The half-life is 8.5 hours and has a wide range (approximately 1.72‒12 hours). After a single dose, the maximum concentration of carbamazepine in blood plasma in adults is reached in 4‒16 hours (very rarely – in 35 hours), in children – in about 4‒6 hours. Plasma carbamazepine concentrations are not linearly dose-dependent and at higher doses the plasma concentration curve is plateau-like.
The use of prolonged-release tablets achieves a lower concentration of carbamazepine in blood plasma than with conventional tablets.
Equilibrium concentration is reached in 2‒8 days.
Regarding therapeutic and toxic concentrations of carbamazepine in blood plasma, it is indicated that seizures may disappear when its level in blood plasma is 4‒12 μg / ml. Plasma concentrations of the drug in excess of 20 μg / ml worsen the disease.
Indication
Epilepsy:
complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization;
generalized tonic-clonic seizures;
mixed forms of seizures.
Finlepsin® 200 retard can be used as monotherapy or as part of combination therapy.
Acute manic states; maintenance therapy for bipolar disorder to prevent exacerbations or to reduce the clinical manifestations of exacerbations.
Alcohol withdrawal syndrome.
Idiopathic trigeminal neuralgia and trigeminal neuralgia in multiple sclerosis (typical and atypical).
Idiopathic lingual-pharyngeal nerve neuralgia.
Contraindication
Finlepsin® 200 retard should not be prescribed:
Recent Reviews